WXPRESS is your window into the world of WuXi AppTec and our global partners. WXPRESS gives you an insider’s perspective on our collaborative efforts to develop innovative medicines that improve the lives of patients. With first-hand insights from executives on the frontline of drug development and all the news from WuXi and our partners, WXPRESS is the monthly monitor of the what, when and why of the global biopharma industry.

Please enjoy past issues of our newsletters below:

WXPRESS (focused on WuXi news and the global life science community)

BAYpress (focused on San Francisco Bay Area life science community)

MApress (focused on Massachusetts life science community)

SDpress (focused on San Diego and southern California life science community)

ILpress (focused on Israel life science community)

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi NextCODE Completes $240 Million Series B Financing

We are pleased to announce that WuXi NextCODE has successfully completed a $240 million Series B financing. The company extended and completed the Series...